A compassionate use trial to investigate the safety and efficacy of dendritic cell vaccines in patients with various types of tumours

Trial Profile

A compassionate use trial to investigate the safety and efficacy of dendritic cell vaccines in patients with various types of tumours

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
  • Indications Acute myeloid leukaemia; Glioblastoma; Lung cancer; Prostate cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Results published in the MediGene AG Media Release
    • 04 Apr 2017 Results (n = 5) were presented at the American Association for Cancer Research (AACR) Annual Meeting, according to a MediGene AG media release.
    • 11 May 2016 Results (n = 5) were presented at the 14th Cancer Immunotherapy Conference (CIMT), according to a MediGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top